ITLN1 and glucose metabolism disease: Most scientific evidence shows reduced omentin levels in patients with glucose metabolism disorders, such as diabetes type 1 and type 2, impaired glucose tolerance, and gestational diabetes, compared to healthy individuals [30,31,32,33].